$219 Million is the total value of INTERNATIONAL BIOTECHNOLOGY TRUST PLC's 57 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 42.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VRTX | Sell | Vertex Pharmaceuticals Inc | $18,517,000 | -9.4% | 77,822 | -16.7% | 8.44% | +14.6% |
| GILD | Sell | Gilead Sciences Inc | $17,718,000 | -7.0% | 237,284 | -19.1% | 8.08% | +17.7% |
| NBIX | Sell | Neurocrine Biosciences Inc | $9,288,000 | -35.1% | 107,300 | -19.5% | 4.23% | -17.9% |
| ALXN | Sell | Alexion Pharmaceuticals Inc | $6,611,000 | -29.0% | 73,641 | -14.5% | 3.01% | -10.1% |
| SGEN | Sell | Seattle Genetics Inc | $6,557,000 | -10.3% | 56,900 | -11.1% | 2.99% | +13.5% |
| SRPT | Sell | Sarepta Therapeutics Inc | $2,744,000 | -47.0% | 28,100 | -29.9% | 1.25% | -32.9% |
| ALNY | Sell | Alnylam Pharmaceuticals Inc | $2,425,000 | -51.4% | 22,300 | -48.5% | 1.10% | -38.5% |
| KALV | Sell | Kalvista Pharmaceuticals Inc | $1,731,000 | -64.8% | 227,433 | -18.0% | 0.79% | -55.5% |
| XLRN | Sell | ACCELERON PHARMA INC | $1,617,000 | -46.5% | 18,000 | -68.4% | 0.74% | -32.3% |
| AMRN | Sell | Amarin Corp Plcspons adr new | $1,274,000 | -84.7% | 320,000 | -17.5% | 0.58% | -80.6% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $1,193,000 | -60.5% | 67,000 | -52.1% | 0.54% | -50.0% |
| SAGE | Sell | Sage Therapeutics Inc | $1,077,000 | -63.9% | 37,600 | -9.2% | 0.49% | -54.3% |
| AGIO | Sell | Agios Pharmaceuticals Inc | $762,000 | -56.3% | 21,500 | -41.1% | 0.35% | -44.7% |
| MYOK | Sell | Myokardia INC | $743,000 | -66.0% | 15,859 | -47.1% | 0.34% | -56.9% |
| MNTA | Sell | MOMENTA PHARMACEUTICALS INC | $734,000 | -53.4% | 27,000 | -66.2% | 0.34% | -40.9% |
| BPMC | Sell | Blueprint Medicines Corp | $700,000 | -48.6% | 12,000 | -29.4% | 0.32% | -35.0% |
| TCDA | Sell | Tricida Inc | $635,000 | -54.4% | 29,000 | -21.6% | 0.29% | -42.4% |
| BLUE | Sell | Bluebird Bio Inc | $505,000 | -66.1% | 11,000 | -35.3% | 0.23% | -57.2% |
| GBT | Sell | Global Blood Therapeutics | $498,000 | -72.9% | 9,800 | -57.6% | 0.23% | -65.7% |
| ESPR | Sell | ESPERION THERAPEUTICS INC NE | $298,000 | -83.3% | 9,500 | -68.3% | 0.14% | -78.9% |
| GTHX | Exit | G1 Therapeutics Inc | $0 | – | -11,200 | -100.0% | -0.11% | – |
| RDUS | Exit | Radius Health Inc | $0 | – | -17,000 | -100.0% | -0.12% | – |
| MOR | Exit | MORPHOSYS AGsponsored ads | $0 | – | -11,295 | -100.0% | -0.14% | – |
| DERM | Exit | Dermira Inc | $0 | – | -30,000 | -100.0% | -0.16% | – |
| SUPN | Exit | Supernus Pharmaceuticals Inc | $0 | – | -19,953 | -100.0% | -0.17% | – |
| AKCA | Exit | AKCEA THERAPEUTICS INC | $0 | – | -31,723 | -100.0% | -0.19% | – |
| MYGN | Exit | Myriad Genetics inc | $0 | – | -25,000 | -100.0% | -0.24% | – |
| IFRX | Exit | INFLARX NV | $0 | – | -220,000 | -100.0% | -0.31% | – |
| GMED | Exit | Globus Med Inc | $0 | – | -24,200 | -100.0% | -0.51% | – |
| BGNE | Exit | BEIGENE LTDsponsored adr | $0 | – | -14,000 | -100.0% | -0.84% | – |
| SGMO | Exit | Sangamo Therapeutics Inc | $0 | – | -303,000 | -100.0% | -0.91% | – |
| NVCR | Exit | NOVOCURE LTD | $0 | – | -35,500 | -100.0% | -1.08% | – |
| ILMN | Exit | ILLUMINA INC | $0 | – | -25,100 | -100.0% | -3.00% | – |
| STML | Exit | Stemline Therapeutics Inc | $0 | – | -965,245 | -100.0% | -3.69% | – |
| REGN | Exit | Regeneron Pharmaceuticals | $0 | – | -28,830 | -100.0% | -3.90% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC COMMO | 28 | Q3 2023 | 9.3% |
| INCYTE CORP INC COM | 28 | Q3 2023 | 7.9% |
| BIOMARIN PHARMACEUTICALS INC | 28 | Q3 2023 | 7.5% |
| REGENERON PHARMS. | 27 | Q3 2023 | 9.0% |
| BIOGEN INC COMMON STOCK | 26 | Q3 2023 | 8.7% |
| VERTEX PHARMS. | 25 | Q3 2023 | 8.4% |
| AMGEN INC COM | 25 | Q3 2023 | 7.9% |
| NEUROCRINE BIOSCIENCES INC | 25 | Q3 2023 | 6.9% |
| ALYNYLAM PHARMACEUTICALS INC | 25 | Q3 2023 | 6.7% |
| IONIS PHARMS. | 25 | Q3 2023 | 4.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Altus Pharmaceuticals Inc. | February 12, 2009 | ? | ? |
| MICROMET, INC. | February 14, 2008 | 1,907,390 | 4.7% |
| EPIMMUNE INC | February 15, 2005 | 1,279,659 | 8.0% |
| ESSENTIAL THERAPEUTICS INC | April 29, 2003 | 2,500,000 | 11.7% |
| TARGETED GENETICS CORP /WA/ | April 18, 2003 | ? | ? |
| ESSENTIAL THERAPEUTICS INC | November 05, 2001 | 11 | 13.0% |
| ONYX PHARMACEUTICALS INC | October 15, 2001 | 11 | 13.0% |
| CORVAS INTERNATIONAL INC | October 12, 2001 | 11 | 13.0% |
| RIBOZYME PHARMACEUTICALS INC | October 05, 2001 | 11 | 13.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-18 |
| 13F-HR | 2023-02-01 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-20 |
| 13F-HR | 2022-02-15 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.